New possibilities to achieve increased understanding of disease mechanisms in idiopathic inflammatory myopathies

Current Opinion in Rheumatology

Volumn 14, Issue 6, 2002, Pages 639-642

  Lundberg, Ingrid E ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTILIPEMIC AGENT; CALCIUM ION; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; THROMBOSPONDIN; UBIQUINONE;

CALCIUM TRANSPORT; CHRONIC INFLAMMATION; CLINICAL RESEARCH; DERMATOMYOSITIS; DUCHENNE MUSCULAR DYSTROPHY; ENERGY METABOLISM; FATIGUE; GENE CONTROL; GENE EXPRESSION; HUMAN; IDIOPATHIC DISEASE; MUSCLE BIOPSY; MUSCLE FUNCTION; MYOPATHY; MYOSITIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOGENESIS; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; RISK FACTOR;

GENE EXPRESSION; GENETIC TECHNIQUES; HUMANS; MOLECULAR BIOLOGY; MUSCLE, SKELETAL; MYOSITIS;

EID: 0036839184     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200211000-00001     Document Type: Review

References (20)

1. Clarke AE, Bloch DA, Medsger TA Jr, et al.: A longitudinal study of functional disability of patients with polymyositis/dermatomyositis. Arthritis Rheum 1995, 38:1218-1224.
2. Maini RN, Breedveld FC, Kalden JR, et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552-1563.
3. Dorph C, Nennesmo I, Lundberg I: The percutaneous conchotome muscle biopsy; a useful diagnostic and assessment tool. J Rheumatol 2001, 28:1591-1599.
4. Miller FW, Rider LG, Chung YL, et al.: Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatol 2001, 40:1262-1273.
5. Hicks J, Wesley R, Koziol D, et al.; For the JDM Disease Activity Collaborative Study Group. Preliminary validation of abbreviated manual muscle testing (MMT) in the assessment of juvenile dermatomyositis (JDM). Arthritis Rheum 2000, 43(suppl):S195.
6. Feldman BM, Ayling-Campos A, Luy L, et al.: Measuring disability in juvenile dermatomyositis: validity of the childhood health assessment questionnaire. J Rheumatol 1995, 22:326-331.
7. Huber A, Hicks JE, Lachebruch PA, et al.: Validation of the Childhood Health Assessment Questionnaire (CHAQ) in the juvenile idiopathic inflammatory myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. J Rheumatol 2001, 28:1106-1111.
8. Lovell DJ, Lindsley CB, Rennebohm RM, et al.: Development of validated disease activity and damage indices for juvenile idiopathic inflammatory myopathies, II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum 1999, 42:2213-2219
9. Isenberg D, Rider L, Ehrenstein M, et al.: For the International Myositis Disease Outcome Assessment Collaborative Study Group. Development of disease activity and damage indices for myositis: initial testing of four tools in adult onset patients. (suppl) Arthritis Rheum 2001, S263.
10. Oddis CV, Sciurba FC, Elmagd KA, et al.: Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 1999, 353:1762-1763.
11. Alexanderson H, Lundberg IE, Stenström CH: Development of the myositis activities profile-validity and reliability of a self-administrated questionnaire to assess activity limitations in patients with polymyositis/dermatomyositis. J Rheumatol, in press.
12. Josefson A, Romanus E, Carlsson J: A functional index in myositis. J Rheumatol 1996, 23:1380-1384.
13. Feldman BM, Rider LG, Dugan L, et al.: Nailfold capillaries as indicators of disease activity in juvenile idiopathic inflammatory myopathies. Arthritis Rheum 1999, 42(suppl):S181.
14. Huber AM, Lang B, LeBlanc CM, et al.: Medium and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000, 43:541-549
15. Tezak Z, Hoffman EP, Lutz JL et al.: Gene expression profiling in DQA1*0501+ Children with untreated dermatomyositis: a novel model for pathogenesis. J Immunol 2002, 168:4154-4163.
16. Chen YW, Zhao P, Borup R, et al.: Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology. J Cell Biol 2000, 12:1321-1336
17. Park JH, Vital TL, Ryder NM, et al.: Magnetic resonance imaging and p-31 magnetic resonance spectroscopy provide unique quantitative data useful in the longitudinal management of patients with dermatomyositis, Arthritis Rheum 1994, 37:736-746.
18. Askanas V, Engel WK: Inclusion-body myositis: newest concepts of pathogenesis and relation to aging and Alzheimer disease. J Neuropathol Exp Neurol 2001, 60:1-14
19. Niermann KJ, Olsen NJ, Park JH: Magnesium Abnormalities of Skeletal muscle in dermatomyositis and juvenile dermatomyositis. Arthritis Rheum 2002, 46:475-488
20. Targoff IN, Miller FW, Medsger TA Jr., et al.: Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol 1997, 9:527-535.